Aurinia Pharmaceuticals（AUPH）株式概要
バイオ医薬品会社であるオーリニア・ファーマシューティカルズ・インクは、米国と日本において、アンメット・メディカル・ニーズの高い自己免疫疾患に苦しむ人々に治療薬を提供することに取り組んでいる。 詳細
AUPH Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aurinia Pharmaceuticals Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$15.61 |
| 52週高値 | US$19.25 |
| 52週安値 | US$7.36 |
| ベータ | 1.41 |
| 1ヶ月の変化 | -1.45% |
| 3ヶ月変化 | -1.14% |
| 1年変化 | 108.97% |
| 3年間の変化 | 45.48% |
| 5年間の変化 | 25.28% |
| IPOからの変化 | 661.46% |
最新ニュース
ナラティブの更新 • Jun 24
AUPH: Future Rerating Will Rely On Autoimmune Pipeline Expansion
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals unchanged at $20.85 per share, making only modest adjustments to assumptions on the discount rate, revenue growth, profit margin, and future P/E based on recent peer takeover valuations and updated Street research. What's in the News for Aurinia Pharmaceuticals Aurinia Pharmaceuticals stock rose 6.5% on higher-than-average trading volume, with investors focused on growth potential beyond lead drug Lupkynis, according to recent coverage citing a P/E of 7.24 and a sector valuation ranking of 288 out of 388 (source: Zacks / recent news reports).分析記事 • Jun 17
Aurinia Pharmaceuticals (AUPH) Stock Could Be 4.6% Undervalued After New LUPKYNIS Phase 3 Data
Aurinia Pharmaceuticals (AUPH) is back in focus after presenting new AURORA 1 Phase 3 data at the EULAR 2026 Congress, highlighting LUPKYNIS outcomes in adults with lupus nephritis. See our latest analysis for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals stock has gained momentum recently, with a 30 day share price return of 6.15% and a 90 day share price return of 15.20%. The 1 year total shareholder return of 105.06% and 3 year total shareholder return of 69.49% point to strong longer...
ナラティブの更新 • Jun 05
AUPH: Kidney Outcomes Data And Capital Moves Will Shape Balanced 2026 Outlook
Analysts now see Aurinia Pharmaceuticals' fair value holding steady at $17.00 per share, with a slightly lower discount rate and marginally adjusted revenue growth, profit margin, and future P/E assumptions supporting the updated target range following recent sector M&A comparisons. What's in the News LUPKYNIS data from the AURORA 1 Phase 3 study presented at the EULAR 2026 Congress show a statistically significant 53% reduction in risk of renal related events or death for lupus nephritis patients, with additional signals on death, treatment failure, and worsening proteinuria, according to the new analysis.Recent updates
ナラティブの更新 • Jun 24
AUPH: Future Rerating Will Rely On Autoimmune Pipeline Expansion
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals unchanged at $20.85 per share, making only modest adjustments to assumptions on the discount rate, revenue growth, profit margin, and future P/E based on recent peer takeover valuations and updated Street research. What's in the News for Aurinia Pharmaceuticals Aurinia Pharmaceuticals stock rose 6.5% on higher-than-average trading volume, with investors focused on growth potential beyond lead drug Lupkynis, according to recent coverage citing a P/E of 7.24 and a sector valuation ranking of 288 out of 388 (source: Zacks / recent news reports).分析記事 • Jun 17
Aurinia Pharmaceuticals (AUPH) Stock Could Be 4.6% Undervalued After New LUPKYNIS Phase 3 Data
Aurinia Pharmaceuticals (AUPH) is back in focus after presenting new AURORA 1 Phase 3 data at the EULAR 2026 Congress, highlighting LUPKYNIS outcomes in adults with lupus nephritis. See our latest analysis for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals stock has gained momentum recently, with a 30 day share price return of 6.15% and a 90 day share price return of 15.20%. The 1 year total shareholder return of 105.06% and 3 year total shareholder return of 69.49% point to strong longer...ナラティブの更新 • Jun 05
AUPH: Kidney Outcomes Data And Capital Moves Will Shape Balanced 2026 Outlook
Analysts now see Aurinia Pharmaceuticals' fair value holding steady at $17.00 per share, with a slightly lower discount rate and marginally adjusted revenue growth, profit margin, and future P/E assumptions supporting the updated target range following recent sector M&A comparisons. What's in the News LUPKYNIS data from the AURORA 1 Phase 3 study presented at the EULAR 2026 Congress show a statistically significant 53% reduction in risk of renal related events or death for lupus nephritis patients, with additional signals on death, treatment failure, and worsening proteinuria, according to the new analysis.Seeking Alpha • Jun 04
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
Summary Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH’s valuation and future pipeline or strategic optionality. The Kezar acquisition diversifies AUPH’s autoimmune platform, adding zetomipzomib with multi-indication potential and a risk-mitigated deal structure. Read the full article on Seeking Alphaナラティブの更新 • May 21
AUPH: Future Rerating Will Rely On Sector Takeout Benchmarks
Narrative Update on Aurinia Pharmaceuticals Analysts now frame Aurinia Pharmaceuticals with a slightly revised price target of about $20.85 from $21.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E after reviewing recent sector takeout valuations. Analyst Commentary Recent commentary links Aurinia Pharmaceuticals to broader sector M&A activity, with bullish analysts pointing to the Kezar Life Sciences takeover valuation as a useful reference point for what acquirers have been willing to pay for comparable assets.分析記事 • May 15
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions
We didn't see Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) stock surge when it reported robust earnings recently. We...ナラティブの更新 • May 05
AUPH: Sector Deal Benchmarks And 2026 Outlook Will Support Balanced Case
Analysts maintained their $17.00 price target for Aurinia Pharmaceuticals, citing updated model inputs and recent sector deal activity as supporting factors for their view of the stock’s current valuation. Analyst Commentary Bullish Takeaways Bullish analysts point to the Kezar Life Sciences takeover valuation as a helpful reference point, suggesting that recent transaction pricing in the sector supports the maintained US$17.00 target for Aurinia Pharmaceuticals.
ナラティブの更新 • Apr 20
AUPH: Future Returns Will Depend On Execution And Disciplined Takeover Multiples
Analysts have kept their fair value estimate for Aurinia Pharmaceuticals steady at $15.00. They cite updated modeling that slightly adjusts the discount rate, revenue growth outlook, profit margin assumptions, and forward P/E multiple in light of recent peer takeover valuations in the biotech space.ナラティブの更新 • Apr 06
AUPH: Richer Future P/E Will Rely On Executing Post Takeover Hopes
Analysts have raised their price target on Aurinia Pharmaceuticals to $15.00 from $13.00, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E, informed in part by recent takeover valuation discussions in the sector. Analyst Commentary Analysts highlighting the recent Kezar Life Sciences takeover discussion point out that the implied valuation framework is one reference point for Aurinia Pharmaceuticals, but not a firm roadmap.ナラティブの更新 • Mar 23
AUPH: Stable 2026 Outlook And Buyback Progress Will Support Bullish Case
Analysts have kept their $17.00 price target for Aurinia Pharmaceuticals essentially unchanged, citing stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News Aurinia issued earnings guidance for 2026, projecting total revenue in a range of $315 million to $325 million.ナラティブの更新 • Mar 08
AUPH: Higher 2026 Outlook And Margin Assumptions Will Support Bullish Case
Analysts have nudged their fair value estimate for Aurinia Pharmaceuticals from $16.67 to $17.00, reflecting updated assumptions around a slightly lower revenue growth outlook, a modestly higher profit margin, a small adjustment to the discount rate, and a higher future P/E multiple. What's in the News Aurinia issued 2026 earnings guidance, with total revenue expected in a range of $315 million to $325 million, and net product sales projected between $305 million and $315 million, both framed relative to 2025 levels (Key Developments).ナラティブの更新 • Feb 22
AUPH: Richer Future P/E Will Heighten Risk From Lower Profitability
Analysts have raised their fair value estimate for Aurinia Pharmaceuticals from $9.00 to $13.00 per share, citing updated assumptions that combine a higher projected revenue growth rate with a richer future P/E multiple and a lower expected profit margin profile. Valuation Changes Fair Value: increased from $9.00 to $13.00 per share, representing a sizeable uplift in the intrinsic value estimate.ナラティブの更新 • Feb 08
AUPH: Refined Discount Rate And Margins Will Support More Constructive Outlook
Analysts have adjusted their price target for Aurinia Pharmaceuticals to US$16.67. The updated view reflects slightly higher discount rate and profit margin assumptions, along with a modest tweak to projected revenue growth and future P/E.ナラティブの更新 • Jan 25
AUPH: Future Rerating Will Hinge On Aritinercept Development Clarity
Analysts have modestly increased their price target on Aurinia Pharmaceuticals to $15, up from $9, citing stronger than expected Lupkynis sales, improved operating leverage, and a desire for more clarity around aritinercept's development path before taking a more aggressive stance. Analyst Commentary Recent research reflects a more balanced stance on Aurinia Pharmaceuticals, even as the official price target is now set at $15, compared with the prior $9 level.ナラティブの更新 • Jan 10
AUPH: Higher Fair Value View Will Hinge On Lupus Nephritis Franchise
Analysts have raised their price target on Aurinia Pharmaceuticals from $16.46 to $21.00, reflecting updated assumptions on growth, profitability, and future P/E. They also highlight Lupkynis performance and the recent shift to a Sector Perform rating as key context for the revised outlook.ナラティブの更新 • Dec 17
AUPH: Legal Overhang And Pipeline Clarity Will Shape Balanced Near-Term Outlook
Analysts have nudged their fair value estimate for Aurinia Pharmaceuticals slightly higher to about $16.67 from $16.50, citing stronger than anticipated Lupkynis sales, improved operating leverage, and a more balanced risk reward profile that tempers the prior upside skew. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Lupkynis sales have materially outperformed initial expectations, reinforcing confidence in the durability of the core nephrology franchise and supporting higher revenue run rate assumptions.ナラティブの更新 • Dec 03
AUPH: Legal Overhang And Pipeline Uncertainty Will Likely Define Near-Term Performance
Analysts have modestly increased their price target on Aurinia Pharmaceuticals to approximately $16.50 per share from around $15.00, citing stronger than expected Lupkynis sales, improved operating leverage, and a more balanced risk reward profile, while noting that some caution is still warranted until there is greater clarity on aritinercept's development path. Analyst Commentary Recent commentary reflects a more balanced stance on Aurinia Pharmaceuticals, with valuation catching up to improving fundamentals and leaving less room for multiple expansion without new catalysts.ナラティブの更新 • Nov 19
AUPH: Risk And Opportunity Dynamics Will Likely Shape Performance Heading Into 2025
Narrative Update on Aurinia Pharmaceuticals Analysts have raised their price target for Aurinia Pharmaceuticals from $13 to $16.50 per share. They cite continued strong Lupkynis sales and improved operating leverage as key factors behind the increased valuation.分析記事 • Nov 08
Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 27% share price jump...ナラティブの更新 • Nov 05
AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments
Analysts have raised their fair value price target for Aurinia Pharmaceuticals from $11.71 to $13.00. They cite stronger-than-expected Lupkynis sales and improved profit margins as key factors supporting this upward revision.分析記事 • May 19
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality
The subdued stock price reaction suggests that Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) strong earnings didn't...分析記事 • May 15
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just released its latest quarterly results and things are looking bullish...分析記事 • May 09
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Aurinia Pharmaceuticals to hold its Annual General Meeting on 15th of May CEO Peter Greenleaf's total...
新しいナラティブ • Apr 28
Academic Medical Centers Will Expand Lupus Care Opportunities
Expansion into medical centers and new treatment guidelines may drive higher prescriber engagement and revenue for LUPKYNIS.Seeking Alpha • Apr 26
Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
Summary AUPH has seen some management changes, but activist investors demand more despite steady Lupkynis sales growth. The first quarter was strong in terms of sales in 2023 and 2024, and upcoming Q1 '25 earnings represent an opportunity to confirm that trend. AUPH is also expected to report the first clinical data from AUR200 in Q2 '25, which might allow the opportunity for the company to one day grow beyond revenues from Lupkynis. Read the full article on Seeking Alpha分析記事 • Apr 01
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues
Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a buy...分析記事 • Mar 02
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 21
Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Summary AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appears achievable, with $158.6M already reported and Q4 typically outperforming Q3. Potential competitors in lupus nephritis and even in systemic lupus erythematosus include Roche and Biogen. Read the full article on Seeking Alpha分析記事 • Dec 11
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25%
Despite an already strong run, Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shares have been powering on, with a gain...Seeking Alpha • Nov 08
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Summary Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years. The actions the company is taking also look like Aurinia is preparing itself to be acquired, an event that has been rumored consistently in recent years. An updated analysis around Aurinia Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 30% share price jump...Seeking Alpha • Jul 05
Aurinia Pharmaceuticals Appears Undervalued
Summary Aurinia Pharmaceuticals stock has dropped more than 80% due to disappointing Lupkynis sales since its launch in 2021. Management is focusing solely on driving Lupkynis sales and cutting costs by laying off 25% of its sales force and discontinuing other programs. With positive cash flow expected soon, a $150 million share repurchase plan, and strong financials, Aurinia is undervalued and worth considering for investment. A full investment analysis around Aurinia Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
As you might know, Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) just kicked off its latest quarterly results with some...Seeking Alpha • May 02
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
Summary AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug is out-licensed. AUPH bought back 3.4M shares through April 30, at an average price of $5.37 per share. Read the full article on Seeking AlphaSeeking Alpha • Apr 18
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Summary Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential increase in US sales and from international markets paired with cost savings could make Aurinia cash flow positive by the end of the year. Future patent challenge to Lupkynis is likely, but defendable. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Summary AUPH's strategic review did not result in an acquisition of the company, nor the company acquiring an asset. AUPH has decided to buy back its own stock and focus on Lupkynis. The buyback could provide support for the stock near-term, although a return to strong sales growth would provide better support for the bull thesis. Read the full article on Seeking Alpha分析記事 • Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
There's been a major selloff in Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shares in the week since it released its...分析記事 • Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) share price has dived 26% in the...Seeking Alpha • Feb 15
Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Summary Aurinia Pharmaceuticals Inc. stock price dropped 25% after underwhelming Q4 and full-year 2023 results. Sales of Lupkynis, indicated for lupus nephritis and the company's only commercial product, have failed to meet expectations. Aurinia has initiated a strategic review, exploring alternatives including a potential sale, but has been unable to find a buyer. Lupkynis appears to be an effective drug, however, its patents may expire in 2025, allowing generic drugs to enter the market, undercut on price. In short, the outlook for Aurinia in 2025 does not look good. The company is guiding for $200m — $220m of Lupkynis revenues, but profits are elusive, and the company directionless, it seems. Read the full article on Seeking Alpha株主還元
| AUPH | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -7.0% | 4.1% | 1.6% |
| 1Y | 109.0% | 41.1% | 18.6% |
業界別リターン: AUPH過去 1 年間で41.1 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: AUPH過去 1 年間で18.6 % の収益を上げたUS市場を上回りました。
価格変動
| AUPH volatility | |
|---|---|
| AUPH Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: AUPH 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: AUPHの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1993 | 128 | Kevin Tang | www.auriniapharma.com |
バイオ医薬品企業であるオーリニア・ファーマシューティカルズ・インクは、米国および日本において、アンメット・メディカル・ニーズの高い自己免疫疾患患者への治療薬の提供に取り組んでいる。同社は活動性ループス腎炎の成人患者を対象とした経口治療薬LUPKYNIS（一般名：ボクロスポリン）を提供している。また、自己免疫疾患の治療薬として、B細胞活性化因子と増殖誘導リガンドの二重阻害剤であるアリチネルセプトの開発も行っている。同社は1993年に設立され、カナダのエドモントンに本社を置いている。
Aurinia Pharmaceuticals Inc. 基礎のまとめ
| AUPH 基礎統計学 | |
|---|---|
| 時価総額 | US$2.01b |
| 収益（TTM） | US$298.21m |
| 売上高(TTM) | US$298.30m |
6.7x
PER（株価収益率6.7x
P/SレシオAUPH は割高か？
公正価値と評価分析を参照収益と収入
| AUPH 損益計算書（TTM） | |
|---|---|
| 収益 | US$298.30m |
| 売上原価 | US$64.83m |
| 売上総利益 | US$233.47m |
| その他の費用 | -US$64.75m |
| 収益 | US$298.21m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 2.32 |
| グロス・マージン | 78.27% |
| 純利益率 | 99.97% |
| 有利子負債／自己資本比率 | 0% |
AUPH の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/06 05:57 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Aurinia Pharmaceuticals Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| David Martin | Bloom Burton & Co. |
| Dae Gon Ha | BTIG |
| Neil Maruoka | Canaccord Genuity |